Fluicell AB Enters into Lucrative Licensing Agreement with Ambusol
Stockholm, September 2, 2025 — Fluicell AB, a biotechnology company based in Gothenburg, Sweden, has entered into an exclusive and global licensing and development agreement with Ambusol AB. This agreement involves the use of Fluicell’s microfluidics platform, Nexocyte, and the development of a new catheter technology tailored for Ambusol, aimed at cancer treatment.
The deal is valued at up to 142 million SEK, structured as follows: an upfront payment of 1.5 million SEK, ongoing licensing payments of 29 million SEK, and up to 111.5 million SEK in milestone payments contingent on achieving specific results across five cancer indications. These indications include glioblastoma, with subsequent applications in prostate, breast, skin, and pancreatic cancer.
Fluicell will conduct the necessary research and development to adapt its technology for this purpose, compensated at market rates by Ambusol. Additionally, Fluicell will receive royalties from future sales of the treatment. Through this agreement, Ambusol gains an exclusive global license to apply and commercialize Fluicell’s technology and patent portfolio for therapeutic fluid flow control.
This strategic partnership underscores Fluicell’s commitment to advancing cancer treatment technologies and highlights Sweden’s leadership in technical innovation within the healthcare sector. Fluicell’s stock, listed on the Swedish Stock Exchange, closed at 9.6 SEK on August 31, 2025, with a market capitalization of 14.15 million SEK. Despite a negative price-to-earnings ratio of -0.003, the company’s recent developments suggest potential growth opportunities.
Fluicell AB continues to serve universities, the pharmaceutical industry, and national health laboratories in Sweden, leveraging its expertise in single-cell discovery platforms for biomedicine, drug development, and bioprinting. For more information, visit www.fluicell.com .